Biogen's Tender Offer for Apellis Clears HSR Regulatory Hurdle
APLS has more than doubled off its 52-week low of $16.1.
Summary
Biogen's tender offer for Apellis Pharmaceuticals has cleared a major regulatory hurdle with the expiration of the HSR waiting period, moving the acquisition closer to closing.
Key Events · M&A and Partnerships · APLS
-
HSR Waiting Period Expired
The Hart-Scott-Rodino (HSR) Act waiting period for the tender offer expired on May 11, 2026, satisfying a critical regulatory condition for the acquisition.
-
Merger Condition Met
This clearance fulfills a key condition for Biogen's $41.00 per share cash plus CVR acquisition of Apellis Pharmaceuticals, advancing the merger towards completion.
Analysis · APLS · Life Sciences
This amendment confirms that the waiting period under the Hart-Scott-Rodino (HSR) Act has expired, satisfying a key regulatory condition for Biogen's acquisition of Apellis Pharmaceuticals. This removes a significant regulatory risk and brings the $5.6 billion merger closer to completion. The stock is currently trading near its 52-week high, reflecting market confidence in the deal's closing.
At the time of this filing, APLS was trading at $41.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3B. The 52-week trading range was $16.10 to $41.14. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.